Carrico J, Jia X, Zhao Y, et al. Cost-effectiveness, budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs [abstract L14]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Advertisement
Articles by Carrico J, Jia X, Zhao Y, et al. Cost-effectiveness, budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs [abstract L14]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Clears First Alzheimer Blood Test for Adults as Young as 40
2
MFN Drug Agreements Could Raise Prices Worldwide
3
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
4
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
5